Cavina, L.; Bouma, M.J.; Gironés, D.; Feiters, M.C.
Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition. Molecules 2024, 29, 4047.
https://doi.org/10.3390/molecules29174047
AMA Style
Cavina L, Bouma MJ, Gironés D, Feiters MC.
Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition. Molecules. 2024; 29(17):4047.
https://doi.org/10.3390/molecules29174047
Chicago/Turabian Style
Cavina, Lorenzo, Mathijs J. Bouma, Daniel Gironés, and Martin C. Feiters.
2024. "Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition" Molecules 29, no. 17: 4047.
https://doi.org/10.3390/molecules29174047
APA Style
Cavina, L., Bouma, M. J., Gironés, D., & Feiters, M. C.
(2024). Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition. Molecules, 29(17), 4047.
https://doi.org/10.3390/molecules29174047